BioSpace News Archive

Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?

Abeona Therapeutics’ shares popped 18.32% in pre-market trading after New York and Cleveland-based company announced magnetic resonance imaging (MRI) data from its Phase I/II Transpher A trial in San Filippo Syndrome Type A (MPS IIIA).

The urinary catheters market was valued at US$ 2,526.8 million in 2017 and it is projected to reach US$ 4,811.0 million in 2025; it is expected to grow at a CAGR of 8.6% from 2017 to 2025.

Bristol Myers Squibb (BMS) announced Friday its decision to withdraw from the U.S. market the indication for its immune checkpoint inhibitor Opdivo® (nivolumab) as monotherapy for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.

Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.

Laekna Therapeutics, an emerging innovative pharma company based in China’s “Zhangjiang Pharma Valley” and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology Congress 2021.

Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.

Allarity Therapeutics A/S and Lantern Pharma Inc. announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical development and commercialization.

Sarika – the first woman to receive heat-stable carbetocin, with her husband, newborn son and the first doctor to administer, Dr Yeshita V Pujar, Karnataka, India